AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03006159
Drug: SHR0534
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03006159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05422677
Drug: Hanmi Tams® Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hanmi Tams®, Once daily administered per the locally approved product information
Trial: NCT02742987
Drug: Standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Trial: NCT03807011
Drug: fentanyl group
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 2 μg/kg
Trial: NCT03807011
Drug: remifentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 0.2 μg/kg/min
Trial: NCT04287777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of Placebo (ointment) TID during 7 days
Trial: NCT04571710
Drug: SHR1258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR1258 400mg
Trial: NCT01217970
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02057471
Drug: Intravenous ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
Trial: NCT04425733
Drug: MK-5475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
Trial: NCT04425733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5475-matching placebo administered QD via inhalation
Trial: NCT01391390
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/day, 12-week treatment
Trial: NCT01391390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/day, 12-week treatment for TD
Trial: NCT03689998
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical application of melatonin
Trial: NCT01516957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC (subcutaneous)
Trial: NCT03131336
Drug: PeproStat
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for local application
Trial: NCT04139122
Drug: SJP-0132
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJP-0132 is administered as an eye drop
Trial: NCT04139122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered as an eye drop
Trial: NCT02763852
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.
Trial: NCT02763852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
Trial: NCT02763852
Drug: Madopar® 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
Trial: NCT01042704
Drug: Prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
Trial: NCT03942198
Drug: Taodan Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Trial: NCT03942198
Drug: Taodan Granules Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Trial: NCT03623698
Drug: Nebulised hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised hypertonic saline used for a period of at least 12 months
Trial: NCT00939276
Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Trial: NCT00939276
Drug: Nepafenac ophthalmic suspension vehicle
RxNorm normalized name: nepafenac Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Trial: NCT00390533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration (capsules)
Trial: NCT00654407
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00654407
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02344680
Drug: Anti-HIV Agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00295347
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02556268
Drug: Antiretroviral protease inhibitor
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
Trial: NCT01996826
Drug: Avastin® (bevacizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
Trial: NCT01996826
Drug: 0.9% NaCl & Refresh Liquigel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
Trial: NCT00695396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching volume 2 mLfor 48 weeks
Trial: NCT00695396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching volume 1 mL for 48 weeks
Trial: NCT01545297
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
Trial: NCT01312818
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
Trial: NCT01239771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subjects in each cohort will be given placebo.
Trial: NCT01698931
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before each main meal on three separate dosing visits separated by a wash-out period
Trial: NCT03469479
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
Trial: NCT02256761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256761
Drug: BIRT 2584 XX - single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00504439
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-656933-AAA matching placebo tablets will be administered orally.
Trial: NCT00504439
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin will be provided as a 40 mg tablet.
Trial: NCT03752112
Drug: Benzathine penicillin 2.4 million units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
Trial: NCT01456130
Drug: Rapid-acting insulin secretagogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
Trial: NCT00004846
Drug: ABC/Gen-Probe/Chiron HIV-1/HCV 001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00299260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT03302403
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is used for lymphodepletion.
Trial: NCT01316458
Drug: STI571 (Glivec®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03012191
Drug: Gentamicin Sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
Trial: NCT01773967
Drug: LGG
RxNorm normalized name: LGG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGG 10\^10 cfu PO BID X 5 days
Trial: NCT01531582
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
Trial: NCT02954887
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT00754689
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT02274961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02240121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Trial: NCT02389465
Drug: Escitalopram + Celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive celecoxib in addition to escitalopram
Trial: NCT01730612
Drug: TF2 - 68 Ga-IMP-288:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ImmunoTEP
Trial: NCT00815048
Drug: Atropine/Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 20mcg/kg~Remifentanil 3mcg/kg
Trial: NCT00815048
Drug: Fentanyl/Atropine/Succinylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg
Trial: NCT04156568
Drug: INH、RFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6INH 10mg/kg 3INH+RFT 15mg/kg
Trial: NCT01393340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00010075
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00010075
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00255216
Drug: Policosanol supplement (oral capsule) vs. placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00729443
Drug: AZD3241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT00729443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01340664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule taken orally twice daily with a meal for 18 weeks
Trial: NCT02202967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains lactose granules
Trial: NCT00755963
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maltodextrin
Trial: NCT01230138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT00153673
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg bd
Trial: NCT02194946
Drug: CKD-related management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
Trial: NCT05508178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norovirus vaccine (rNV-2v) vehicle without antigen
Trial: NCT02100930
Drug: oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01619761
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04556357
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Trial: NCT02843438
Drug: Anti-toxoplasmosis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02843438
Drug: Anti-inflammatory treatments
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00039039
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00838812
Drug: application of the topic gel
RxNorm normalized name: The Itch Eraser Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
Trial: NCT01467466
Drug: IV isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
Trial: NCT01467466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
Trial: NCT04677543
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablet
Trial: NCT01320345
Drug: Inert lactose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insert lactose tablet matching active tablet administered once daily for 36 months.
Trial: NCT01681667
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
Trial: NCT00375466
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
Trial: NCT02592278
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day brush with fluoride toothpaste.
Trial: NCT03388541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
Trial: NCT00190736
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02795299
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.
Trial: NCT02795299
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.
Trial: NCT02795299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
Trial: NCT02288000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Trial: NCT00945373
Drug: calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% gel
Trial: NCT04271475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive matching placebo tablets orally od.
Trial: NCT00673231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01763333
Drug: BI 1026706 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to BI 1026706
Trial: NCT01973010
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
Trial: NCT03497039
Drug: Diclofenac Diethylamine (DDEA) gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
Trial: NCT04262479
Drug: recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
Trial: NCT02462031
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, 400mg, 800mg
Trial: NCT00459641
Drug: I-040302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
Trial: NCT02263950
Drug: Artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
Trial: NCT01528787
Drug: AR-13324 Ophthalmic Solution 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to study eye, once daily (QD) in the morning (AM) for 7 days